Table 2.
Current risk-predicting scores of hepatocellular carcinoma development in chronic hepatitis B patients without antiviral therapy
| Predicting scores | Predictors | 5-year AUROC to predict HCC risk |
|---|---|---|
| GAG-HCC [18] | Age, male, BCP mutation, cirrhosis, HBV DNA | 0.88 |
| CU-HCC [19] | Age, albumin, bilirubin, cirrhosis, HBV DNA | 0.76 |
| REACH-B [86] | Age, male, ALT, HBeAg-positive, HBV DNA | 0.796 |
| REACH-B II [87] | Age, male, ALT, HBeAg-positive, HBV DNA, HBsAg, genotype, family history of HCC | 0.89 |
| REACH-B IIa [88] | Age, male, ALT, HBeAg-positive, HBV DNA, HBsAg | 0.802–0.815 |
| REACH-B IIb [88] | Age, male, ALT, HBeAg-positive, HBsAg | 0.811–0.823 |
| LSM-HCC [89] | Age, albumin, HBV DNA, LS value | 0.83 |
| RWS-HCC [90] | Age, male, cirrhosis, alpha-fetoprotein | 0.88 |
| D2AS [91] | Age, male, ALT, HBeAg-positive, HBV DNA, REACH-B score | 0.876 |
| AGED [92] | Age, male, HBeAg-positive, HBV DNA | 0.76 |
AUROC, area under receiver operating characteristic; HCC, hepatocellular carcinoma; GAG, guide with age and gender; CU, Chinese University; LSM, liver stiffness measurement; RWS, real-world risk score; BCP, basal core promoter; HBV, hepatitis B virus; ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; LS, liver stiffness.